Seegene, Inc. 096530

The Association for Diagnostics & Laboratory Medicine (ADLM) is pleased to announce the recipients of its 2026 Top Corporate Supporter Award, a distinction given to companies and organizations that generously support the association through advertising, sponsorships, and exhibits. These significant contributions make it possible for ADLM to further its mission of better health for all through laboratory medicine.

Seegene Inc., a global molecular diagnostics company, announced a comprehensive syndromic PCR-based testing approach for reproductive tract infections (RTIs) through the simultaneous detection of sexually transmitted infections (STIs) and human papillomavirus (HPV).

Seegene, Inc. ("Seegene"), a global leader in molecular diagnostics, announced today that its U.S. subsidiary, Seegene USA, Inc. ("Seegene USA"), has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Allplex™ HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR assay designed to simultaneously detect multiple viral pathogens associated with clinically overlapping lesion presentations.

Seegene Inc., a global molecular diagnostics company, announced the launch of the Global Million Clinical Study (GMCS), a large-scale initiative aimed at establishing clinical evidence for a transition from conventional virus-centered testing toward comprehensive syndromic PCR testing that simultaneously detects both viral and pneumonia-associated bacterial pathogens.

Seegene today announced the launch of the Global Million Clinical Study (GMCS), aiming to evaluate the clinical utility and potential impact of comprehensive syndromic PCR testing approaches using real-world data.

As the Asian markets navigate a complex global landscape marked by central banks maintaining steady rates amid geopolitical uncertainties, investors are closely watching how these dynamics influence high-growth sectors, particularly in technology. In this environment, identifying strong tech stocks often involves looking for companies with robust earnings growth potential and resilience against fluctuating commodity prices and economic shifts.

Seegene, a global molecular diagnostics company, announced that it introduced STAgora™, a real-time data analytics platform based on aggregated statistical testing data, and presented an enhanced model of its automated PCR workflow concept CURECA™ at ESCMID Global 2026 (formerly ECCMID), held April 17–21 in Munich, Germany, drawing interest from healthcare professionals attending the event.

As the Asian markets navigate through a complex landscape of economic shifts and policy changes, investors are keenly observing opportunities that may arise from undervalued stocks. In this environment, identifying stocks trading below their intrinsic value can offer potential for growth, especially when market conditions present unique challenges and opportunities.